Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors / 中国当代儿科杂志
Chinese Journal of Contemporary Pediatrics
;
(12): 1072-1077, 2023.
Article
Dans Chinois
| WPRIM
| ID: wpr-1009849
ABSTRACT
Circulating tumor DNA (ctDNA) is emerging as a novel biomarker for tumor evaluation, offering advantages such as high sensitivity and specificity, minimal invasiveness, and absence of radiation. Currently, various techniques including gene sequencing and PCR are employed for ctDNA detection. The utilization of ctDNA for monitoring minimal residual disease (MRD) enables comprehensive assessment of tumor status and early identification of tumor recurrence, achieving a remarkable detection sensitivity of 0.01%. Therefore, ctDNA holds promise as a biomarker for early diagnosis, treatment response monitoring, and prognosis prediction in solid tumors. This article reviews the commonly used methods for detecting ctDNA and their advantages in evaluating tumor MRD and guiding clinical diagnosis and treatment.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pronostic
/
Marqueurs biologiques tumoraux
/
Maladie résiduelle
/
ADN tumoral circulant
/
Récidive tumorale locale
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Chinese Journal of Contemporary Pediatrics
Année:
2023
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS